JWEL:NASDAQJowell Global Ltd. Analysis
Data as of 2026-06-18 - not real-time
$2.65
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
JWEL trades at $2.65, far below its DCF fair value of roughly $39, indicating a massive valuation gap. Technical signals are mixed: the 20‑day SMA (2.37) sits just below the price, the 50‑day SMA (2.41) is slightly above, and the MACD histogram is positive with a bullish signal line, while the RSI hovers around 60, suggesting modest momentum but no overbought condition. Fundamentally, the company shows strong top‑line growth (revenue up 88%) yet remains unprofitable, with negative operating and profit margins, a negative EPS of -2.87, and a high max drawdown of ~46%. Volume is decreasing, and the 30‑day volatility exceeds 80%, underscoring a fragile price environment.
Given the ultra‑low market cap (~$6.3 M) and thin trading, liquidity risk is pronounced, and exposure to the Chinese consumer‑cyclical sector adds regulatory and geographic uncertainties. The stock’s low beta suggests limited systematic risk, but the combination of negative cash flows, high debt‑to‑equity, and a lack of dividend support a cautious stance despite the apparent undervaluation.
Given the ultra‑low market cap (~$6.3 M) and thin trading, liquidity risk is pronounced, and exposure to the Chinese consumer‑cyclical sector adds regulatory and geographic uncertainties. The stock’s low beta suggests limited systematic risk, but the combination of negative cash flows, high debt‑to‑equity, and a lack of dividend support a cautious stance despite the apparent undervaluation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 4/10
Key Factors
- Bullish MACD and RSI near 60 indicate short‑term momentum
- Decreasing volume and high volatility raise execution risk
- Negative earnings and cash flow limit upside potential
Medium Term
1–3 yearsPositive
Model confidence: 5/10
Key Factors
- DCF valuation suggests >1,400% upside
- Revenue growth of 88% provides a potential turnaround catalyst
- Low beta and modest price‑to‑sales ratio support a value‑oriented entry
Long Term
> 3 yearsCautious
Model confidence: 3/10
Key Factors
- Sustained operating losses and negative ROE
- High max drawdown and thin liquidity
- Exposure to Chinese regulatory and consumer‑cyclical headwinds
Key Metrics & Analysis
Financial Health
Revenue Growth87.80%
Profit Margin-3.81%
ROE-44.27%
ROA-13.15%
Debt/Equity13.44
P/B Ratio0.5
Op. Cash Flow$-1530441
Free Cash Flow$2.6M
Technical Analysis
TrendNeutral
RSI59.9
Support$2.12
Resistance$3.00
MA 20$2.37
MA 50$2.41
MA 200$2.19
MACDBullish
VolumeDecreasing
Fear & Greed Index88.5
Valuation
Fair Value$39.59
GradeUndervalued
TypeBlend
Risk Assessment
Beta0.44
Volatility82.41%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskHigh
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.